You are here

Circle of Support


Our Circle of Support is an elite group of industry partners with a mutual interest in stroke awareness and prevention. Learn more about our corporate sponsors and how to become one of them.

National Stroke Association's mission to reduce the incidence and impact of stroke is enabled by the generous support of our Circle of Support. Through Corporate Support, National Stroke Association develops educational programs about all aspects of stroke for the general public, medical professionals, and those touched personally by stroke.

National Stroke Association thanks our Circle of Support members for their dedication to National Stroke Association's mission.

We invite you to join National Stroke Association in our efforts to reduce the incidence and impact of stroke by becoming a member of our Circle of Support. Distinct levels of sponsorship allow you to select a commitment that is consistent with your goals and resources.

For more information about becoming a member of our Circle of Support, please contact us at or 303-754-0909.




As a global leader in medical technology, services and solutions, Medtronic improves the lives and health of millions of people each year. We use our deep clinical, therapeutic and economic expertise to address the complex challenges faced by healthcare systems today. Let’s take healthcare Further, Together. Learn more at

Avanir Pharmaceuticals, Inc

AVANIR Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. We are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. Avanir has an investigational drug in development for pseudobulbar affect (PBA), a neurologic condition characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA occurs in patients with underlying neurologic disease or injury, including stroke. For more information about AVANIR, please visit

Bristol-Myers Squibb/Pfizer Inc Partnership

Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life. We commit to scientific excellence and investment in biopharmaceutical research and development to provide innovative, high-quality medicines that address the unmet medical needs of patients with serious diseases. We apply scientific rigor to produce clinical and economic benefit through medicines that improve patients’ lives.
Pfizer Inc is committed to helping people improve their health by discovering and developing medicines, as well as informing consumers and health care providers about our medicines and the medical conditions they treat. Through multiple initiatives, Pfizer aims to ensure access to treatments and educate, empower and motivate consumers to take the necessary steps to lead longer, healthier, happier lives.  For more information about Pfizer's patient assistance programs, visit

Janssen Pharmaceuticals, Inc.

The Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases.  Driven by our commitment to patients, we bring innovative products, services and solutions to people throughout the world. We recognize the impact of serious conditions on the people's lives, and we aim to empower people through disease awareness, education and access to quality care. Our research and development strategy focuses on identifying the medical needs, and harnessing the best science in the world, whether from our own laboratories, or through strategic relationships and collaborations. For more information visit or


Piramal Group is a global diversified business conglomerate with operations in over 30 countries and a strong presence in more than 100 markets around the world. Since the late 1980s, Piramal Group has evolved from a textile-centric business to a diversified organisation, which operates across sectors such as pharma, health care information management, financial services, specialty glass packaging and real estate. In 2017 Piramal Enterprises Completes the Acquisition of a Portfolio of Drugs for Spasticity and Pain Management from Mallinckrodt LLC. 

Merz Pharmaceuticals

Merz Pharma is an independent international aesthetics and neurotoxin company with its own research and development capabilities. Our continued growth and market leadership in aesthetics and neurotoxins is the result of our drive for innovation, along with focused, strategic acquisitions. We have continued to expand across all areas of our business, due to a focused, purposeful approach that includes both organic and inorganic growth. As a privately-held and family-owned company with a 100 year-plus history, we believe in taking a long-term view. Merz brings an unwavering focus to the specialties we serve, combined with a flexible, responsive approach to the individualized needs of our physician customers and their patients.



Acorda Therapeutics

Millions of people with nervous system disorders are in need of new therapeutic options. We never forget that these people may include our own family members or friends, and that these are not just diseases to be treated, but people who need help to make their lives, and those of their loved ones, better.

Collaboration remains an important part of our DNA. We continue to work with external academic and biopharmaceutical partners to advance the care of people affected by neurological diseases, and are interested in exploring new partnerships that combine compelling science with the potential to bring novel therapies to patients.




Find a Support Group


Get Involved


For over 30 years we have been the trusted source for free resources and education to the stroke community. Together, we empower survivors and their circle of care to thrive after stroke. Make your tax-deductible donation today to support the growing needs of the stroke community.